Torrent Pharma shares in focus as pharma major recalls select batches of Semalix injection

Torrent Pharma shares will be in the spotlight after the drugmaker on Thursday, July 9, said it is implementing a voluntary recall of Semalix injections' disposable pens as a precautionary measure only for select batches.

“This action follows a product recall notification issued by our manufacturer Dr Reddy's Laboratories Ltd., Hyderabad (DRL), for a technical evaluation,” the firm said in a regulatory filing.

However, Torrent said all other stock-keeping units (SKUs) of semaglutide being sold by the company, including the oral formulation, remain completely unaffected.

The affected products include Semalix Injection, specifically select batches of the 2 mg and 4 mg variants manufactured by Dr. Reddy’s Laboratories.

There is no risk to patients already on this treatment because of the recall, the company said.

All other SKUs of semaglutide being sold by Torrent, including the oral formulation, remain completely unaffected, it added.

Furthermore, the company informed that the unaffected products include Semalix tablets in 3 mg, 7 mg, and 14 mg strengths and Sembolic tablets in 3 mg, 7 mg, and 14 mg strengths, both manufactured by Torrent. Additionally, Semalix injection 8 mg manufactured by MSN Laboratories and Sembolic reusable injection manufactured by Zydus Lifesciences remain unaffected.

Earlier on Thursday, Dr Reddy's Laboratories said commercial supplies of its semaglutide product would be delayed due to an active pharmaceutical ingredient (API)-related quality issue.

The company said certain batches of semaglutide were found to be out of specification and that it is investigating the root cause while maintaining that there is no impact on patient safety or the product's existing global regulatory filings.

Semaglutide is a medicine used to treat type 2 diabetes and obesity. It belongs to a class of drugs called GLP-1 receptor agonists, which mimic a natural hormone in the body to help regulate blood sugar levels, slow how quickly food leaves the stomach, and reduce appetite. These effects help improve blood glucose control and support weight loss.

Torrent Pharma share price

On Thursday, Torrent Pharma shares closed at ₹4,898.20 apiece on the National Stock Exchange, rising 0.65%.

From the beginning of the year, Torrent Pharma shares have surged 27%. Over a month’s time, the stock has gained 9%, while it has jumped over 23% in the last six months.

Shares of the company had touched their one-year high of ₹4,948 apiece on July 8, 2026, while their 52-week low of ₹3,295.30 was hit on July 8, 2025.

Torrent Pharma has a total market capitalisation of ₹1.65 lakh crore as of July 9, 2026, according to data on the NSE.